Converison therapy of FOLFIRINOX in patients with unresectable locally advanced pancreatic cancer: A phase II - CFLAP study

Yokohama City University0 个研究点目标入组 50 人开始时间: 2014年5月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Severe drug hypersensitivity 2)Severe dysesthesia with functional disorder 3)homozygote(UGT1A1 *6/*6, UGT1A1 *28/*28) or heterozygote(UGT1A1 *6/*28) 4)Prior treatment(chemotherapy or radiation) 5)Active double cancer (synchronous double cancer or asynchronous double cancer with disease-free duration to be within 5 year) except carcinoma in situ or intramucosal cancer 6)Infections that needs systemic treatment. 7)Pregnant females or being suspected, or nursing mothers. 8)Severe nervous disorder or mental disorder. 9)Transufusion, Blood products and G-CSF tried within 7days before enrollment. 10)Much pleural effusion, ascites fluid, pericardial fluid. 11)Jaundice 12)Congestive heart failure, symptomatic cerebrovascular accident, uncontrolable arrhythmia, and history of myocardial infarction in 12 months 13)Severe interstitial pneumonia or pulmonary fibrosis. 14)Diarrhea(to bring troubles in patients who have stoma) 15)Active peptic ulcer, paresis of intestine and ileus 16)Uncontrolled diabetes mellitus(DM) or DM with nervous disorder. 17)Need continuous medication of atazanavir sulfate. The subject who was determined by investigator that being not adequate to participate in the trial.

发起方